Evidence map›Paper›PMID 40762776›Full record

ArticleAnnals of surgical oncology2025

Impact of Pathologic Complete Response on Local-Regional Recurrence and Survival in Patients Undergoing Neoadjuvant Systemic Therapy and Breast-Conserving Surgery.

Victoria Huynh, Alexa Glencer, Min Yi, Emma Wingate, Hannah Wingate, Naid Allassan, Sarah Alameddine, Puneet Singh, Henry M Kuerer, Kelly K Hunt and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Victoria HuynhDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexa GlencerPalo Alto Medical Foundation, Mountain View, CA, USA.
Min YiDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emma WingateDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hannah WingateDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naid AllassanDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarah AlameddineHouston Christian University, Houston, TX, USA.
Puneet SinghDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Henry M KuererDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly K HuntDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ana Paula RefinettiDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. ACorrea1@mdanderson.org.

Funding

UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)R25CA240137 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN, WATOWICH, STEPHANIE S · 2020 to 2024
$2.1M
Cancer Center Support Grant CA16672NCI NIH HHS R25 CA240137
6 · The paper itself

Abstract

objectiveWe aimed to compare oncologic outcomes between patients achieving pathologic complete response (pCR) versus residual disease (RD) after receiving neoadjuvant systemic therapy (NST) and breast-conserving surgery (BCS).

methodsOur institutional database was used to identify patients treated with NST and BCS for cT1-3N0 invasive breast cancer. Overall survival (OS), disease-specific survival (DSS), local-regional recurrence-free survival (LRRFS), and distant recurrence-free survival (DRFS) rates were compared between patients with pCR and RD. Multivariable analysis was used to identify factors associated with oncologic outcomes.

resultsBetween 1999 and 2015, 732 patients received NST and BCS, with a median follow-up period of 7.1 years. Median age at diagnosis was 52 years. Most patients had clinical T2 (78.8%). pCR differed significantly by tumor subtype, with larger proportions of patients with human epidermal growth factor receptor 2-positive (HER2+; 42.9%) and triple-negative (46.2%) breast cancer (TNBC) achieving pCR compared with hormone receptor-positive (HR+)/HER2-negative (HER2-; 15%) disease (p < 0.0001). Patients achieving pCR had significantly improved 5-year OS (p = 0.002), DSS (p = 0.02), and DRFS (p = 0.01) compared with those with RD. There were no significant differences in LRRFS between patients with pCR and RD, and the 5-year LRR rates were low, except in patients with TNBC and RD. On multivariate analyses, oncologic outcomes differed significantly by tumor subtype, with TNBC subtype associated with worse OS, DSS, LRRFS, and DRFS.

conclusionspCR is associated with improved OS, DSS, and DFRS. LRR rates were low, regardless of pCR or RD, in all tumor subtypes except TNBC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastMastectomy, SegmentalNeoadjuvant TherapyNeoplasm Recurrence, LocalTriple Negative Breast NeoplasmsAdultAgedCarcinoma, LobularCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerBreast-conserving surgeryLocal-regional recurrenceNeoadjuvant chemotherapyOutcomesPathologic complete responseSurvival

Identifiers

PMID40762776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.